Molecular Partners AG

MOLN

Company Profile

  • Business description

    Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

  • Contact

    Wagistrasse 14
    Schlieren
    Zurich8952
    CHE

    T: +41 447557700

    https://www.molecularpartners.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    159

Stocks News & Analysis

stocks

The trillion-dollar club: Are these mega-sized stocks still buys?

The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks

New pricing model for embattled ASX tech leader

Investor day shows off potentially disruptive pricing model.
stocks

Chart of the Week: We see opportunity in Mineral Resources despite debt concerns

Shares trade at a discount despite attractive longer-term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.1019.300.22%
CAC 408,114.747.29-0.09%
DAX 4024,028.14146.110.61%
Dow JONES (US)47,948.2097.260.20%
FTSE 1009,667.0143.86-0.45%
HKSE26,085.08149.180.58%
NASDAQ23,562.2757.130.24%
Nikkei 22550,491.87536.55-1.05%
NZX 50 Index13,483.9931.63-0.23%
S&P 5006,869.7912.670.18%
S&P/ASX 2008,634.6020.500.24%
SSE Composite Index3,902.8127.010.70%

Market Movers